ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO, Pathologists Publish Guideline On Improving Accuracy Of HER2 Testing

December 29, 2006

CT Scanning Use, Costs, Controls Debated By NCAB

October 7, 1977

Preventive Oncology Announcement Withdrawn For Modification

April 3, 1981

NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future

September 20, 1991

NIH Makes Changes To Area Grants

April 25, 1997

Largest Oncological Society Exerts Clout, Getting Results

June 24, 1983